UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Short Term Debt

Last Annual Value

704.00K

3-Year CAGR

101%

5-Year CAGR

52%

10-Year CAGR

23%

UB

Upstream Bio, Inc. Competitors Analysis of Short Term Debt

UPB · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
704.00K
150.1%N/AN/A 
367.00K
N/AN/AN/A
110.00K
N/AN/AN/A
8.14M
N/AN/AN/A
3.77M
N/AN/AN/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
2.21M
N/AN/AN/A
1.11M
N/AN/AN/A
1.12M
N/AN/AN/A
20.50M
N/AN/A21.6%
648.00K
N/AN/AN/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97